Clinical Scorecard: Efficacy and Safety of Short-Duration Radiotherapy Combined with Immunochemotherapy in Rectal Cancer with Proficient Mismatch Repair: A Perioperative Assessment

At a Glance

Key Highlights

• Only ~5% of rectal cancer patients are MSI-H/dMMR and respond well to immunotherapy; 95% are pMMR and typically immunotherapy-insensitive.
• Combining SCRT with immunochemotherapy improves pCR and anal preservation rates compared to conventional neoadjuvant chemoradiotherapy (NCRT) in pMMR rectal cancer.
• Treatment includes 25 Gy in 5 fractions SCRT plus systemic chemotherapy (CAPOX or mFOLFOX6) and immune checkpoint inhibitors (PD-1, PD-L1, or PD-1/CTLA-4 inhibitors) administered over 3–6 months.

Guideline-Based Recommendations

Diagnosis

• Confirm adenocarcinoma by colonoscopy biopsy.
• Determine MMR status by immunohistochemistry (IHC).
• Perform preoperative chest, abdominal, and pelvic enhanced CT/MRI.

Management

• Use SCRT (25 Gy in 5 fractions) combined with systemic chemotherapy and immunotherapy for pMMR rectal cancer.
• Administer concurrent chemotherapy with capecitabine during radiotherapy per NCCN guidelines.
• Consider induction or consolidation chemotherapy with CAPOX or mFOLFOX6.
• Select immune checkpoint inhibitors based on multidisciplinary team evaluation and patient condition.
• Offer 'watch and wait' approach for patients achieving complete clinical response after multidisciplinary assessment.

Monitoring & Follow-up

• Evaluate treatment response via preoperative imaging and postoperative pathology.
• Monitor for perioperative complications and surgical outcomes including sphincter preservation.
• Assess treatment tolerance and completion rates of chemotherapy and immunotherapy.

Risks

• Potential variability in treatment timing and regimen design may affect outcomes.
• Low completion rates of postoperative adjuvant chemotherapy with traditional NCRT.
• Need for individualized decision-making regarding 'watch and wait' to balance risks of recurrence.

Patient & Prescribing Data

Patients with pMMR rectal adenocarcinoma undergoing neoadjuvant therapy at a tertiary cancer center

SCRT combined with immunochemotherapy shows improved pathological response and sphincter preservation compared to conventional long-course NCRT; immunotherapy cycles typically administered every 2–3 weeks for 3–6 months; treatment individualized based on multidisciplinary team recommendations.

Clinical Best Practices

• Perform multidisciplinary team assessments to tailor neoadjuvant therapy regimens including immunotherapy selection and timing.
• Adhere to NCCN and national guidelines for chemotherapy dosing during radiotherapy.
• Use comprehensive preoperative imaging and pathology to evaluate treatment efficacy.
• Consider patient preferences and clinical response when deciding on surgical versus non-surgical management post-neoadjuvant therapy.
• Ensure informed consent with clear communication about immunotherapy benefits and risks.

References

• Immunotherapy efficacy in MSI-H/dMMR colorectal cancer
• Dutch NICHE study on neoadjuvant dual immunotherapy in colon cancer
• Japanese Voltage study on nivolumab consolidation after chemoradiotherapy
• Radiotherapy-induced tumor immune microenvironment modulation
• 2024 Randomized controlled trials on NCRT plus immunotherapy in pMMR rectal cancer